The use of autologous hematopoietic stem cell (HSC) grafts after high-dose chemotherapy protocols may be hampered by contamination of the grafts with tumor cells. Because epithelial cells seem to be the natural hosts of adeno-associated virus 2 (AAV-2), we speculated that epithelial tumor cells in HSC grafts might be selective targets for AAV-2-based vectors. To test this hypothesis, the breast cancer cell lines T47D and MCF-7 were infected with a recombinant AAV-2 vector expressing the green fluorescent protein (GFP) gene; in addition, human CD34 ϩ mobilized peripheral progenitor cells were infected with the same vector. At a multiplicity of infection of 100, only 1.39% Ϯ 0.51% CD34 ϩ cells expressed the GFP gene whereas, 36.06% Ϯ 6.53% of the infected T47D cells and 41.52% Ϯ 3.16% of the infected MCF-7 cells expressed the transduced GFP gene. After further optimizing the transduction procedure by using higher multiplicities of infection (100 -500) and preincubation of samples with the tyrosine kinase inhibitor genistein, up to 82.52% and 85.35% GFP ϩ T47D and MCF-7 cells, respectively, were observed. The GFP fluorescence intensity in transduced mammary tumor cells was up to 3 logs higher than that of transduced CD34 ϩ cells. The differential expression of recombinant AAV-2 vectors in hematopoietic and epithelial tumor cells warrants further research with this vector system, including the use of suicide genes for the purging of autologous HSC grafts. Cancer Gene Therapy (2000) 7, 597-604
T he prognosis of several solid tumors and hematologic malignancies 1, 2 has improved due to high-dose chemotherapy followed by hematopoietic stem cell (HSC) transplantation. Because stem cell grafts may be contaminated by tumor cells, different CD34
ϩ selection procedures as well as purging procedures were developed to remove those contaminants that may give rise to a relapse. [3] [4] [5] Positive selection for the CD34 ϩ antigen is currently the most frequently used purging strategy, achieving a 3-4 log tumor cell depletion in CD34 Ϫ malignancies. 6, 7 Because residual tumor cells were detected after purging, 8 -10 alternative strategies including gene therapeutic approaches are being developed; viral vectors, for instance, can be used as vehicle to transport suicide genes into tumor cells. Retrovirus-based vectors are able to infect both HSCs 11, 12 and tumor cells at a high frequency 13, 14 and are therefore not suited for transduction of a whole stem cell graft with the aim of tumor cell purging. Adeno-associated virus 2 (AAV-2), however, preferentially targets epithelial cells. Wild-type (wt) AAV-2 particles have been observed in cervical 15 as well as in respiratory epithelium. 16 Wt AAV-2 is replication-defective, requiring helper virus functions from adenovirus or herpes virus to replicate efficiently, 17, 18 and has not been associated with any disease as of yet. As demonstrated by Rosenfeld et al 19 and KleinBauernschmitt et al, 20 leptomeningeal spread of solid tumors or solid tumor cell lines seems to be susceptible to AAV-2-mediated gene transfer. Maass et al 21 showed expression of recombinant AAV-2 (rAAV-2) in malignant melanoma, colon carcinoma, and ovarian carcinoma cells and cell lines to produce tumor cell vaccines. Because human CD34 ϩ cells could hardly be infected with AAV-2 and expressed transgenes at very low levels (Ref. 21 and our unpublished observations), we speculated that AAV-2-based vectors might be suitable candidates for new purging strategies targeting malignant epithelial cells in grafts. Because high-dose chemotherapy with autologous HSC grafts is increasingly used in the treatment of breast cancer, improved purging of HSC grafts could contribute to the treatment of this tumor type of utmost importance. To directly compare infection rates of breast cancer cells and hematopoietic progenitor cells in vitro, two breast cancer cell lines (T47D and MCF-7) and human mobilized peripheral blood CD34 ϩ cells were infected with the rAAV-green fluorescent protein (GFP) vector.
The availability of new techniques as well as substances that increase infection rates and the expression of cells by rAAV-2 have been identified recently. In addition to the normal transduction procedures used by most investigators, we tested one of the new substances, genistein. 22 This compound specifically blocks the phosphorylation of the cellular single-stranded D sequencebinding protein (ssD-BP), thereby removing the inhibition of single-stranded (AAV-2 vectors) to double-stranded DNA conversion, which is required for integration of AAV-2 into the genome. An inverse correlation between the phosphorylation state of the ssD-BP and rAAV transduction efficiency has been observed, 22 which could possibly increase gene transfer by rAAV into cells in which the ssD-BP is phosphorylated. This study shows that both higher transduction rates as well as transgene expression could be observed in the breast cancer cell lines compared with mobilized peripheral blood CD34 ϩ progenitors.
MATERIALS AND METHODS

Plasmids
Two plasmids were used for rAAV-2 production: pDG 23 and pTR-UF5 (a generous gift of Dr. Muzyczka, University of Florida, Gene Therapy Center, Gainesville, Fla). The helper plasmid pDG provides all of the genes required for rAAV-2 production in trans; thus, infection of transfected 293T cells with wt adenovirus was not necessary. pTR-UF5 contains the humanized GFP gene under the transcriptional control of the cytomegalovirus promoter, as well as the neomycin resistance gene being driven by the thymidine kinase promoter, all flanked by the AAV-2 inverted terminal repeats.
Production, purification, concentration, and titration of rAAV particles
For the generation of rAAV-2 particles by transient plasmid transfection, 4 ϫ 10 6 293T cells/dish were grown in 10-cm dishes (Becton Dickinson, Plymouth, UK) at 37°C/5% CO 2 . Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Paisley, UK) was used, supplemented with 10% fetal calf serum (FCS) (Sigma, Deisenhofen, Germany) and 0.1 mg/mL penicillin/streptomycin (PS) (Life Technologies). When a confluency of 40 -70% was reached, cells were transfected with 2 g of pTR-UF5 and 6 g of pDG using the calcium phosphate coprecipitation method. The medium was removed after 12 hours and replaced with fresh medium. After another 48 hours of incubation, medium and cells were collected. rAAV-2 particles were released by freeze-thawing (Ϫ80°C to 37°C; four cycles); cell debris was removed by centrifugation, and the supernatants were pooled. The rAAV-containing lysate was concentrated and purified as described previously (modified from Ref. 24) . Briefly, after pre-equilibration with phosphatebuffered saline (PBS), the lysate was loaded on a column containing sulfonated cellulose matrix beads. rAAV-2 particles were eluted with 10 mM phosphate buffer (pH 7.2) containing 1.0 M NaCl after thoroughly washing the column with PBS. Eluted fractions (4 -6 mL each) were purified and concentrated by sucrose-cushion centrifugation by loading them on top of two layers of sucrose (50% and 30%, respectively) and by centrifugation for 5 hours in a Beckman ultracentrifuge (SW40ti swingout-rotor; Beckman, München, Germany) at 250,000 ϫ g. After discarding the supernatant, the pellet was resuspended in 1 mL of Opti-MEM supplemented with 0.1 mg/mL PS (both Life Technologies). For the experiments, five independently produced vector stocks were used.
Titration of biologically active rAAV-2 particles
A total of 5 ϫ 10 3 rep/cap-transduced HeLa cells 25 (HeLa-RC cells)/well were plated into 96-well plates in 100 L of DMEM/ 10% FCS/PS (as described above) and incubated for 24 hours (37°C/5% CO 2 ). On the following day, the different batches of rAAV-2 were titrated on the HeLa-RC cells by limiting dilution spaced in log steps ranging from 1:10 to 1:10 10 . After 2 hours of incubation at 37°C/5% CO 2 , 100 L of wt adenovirus type 5 particles in DMEM were added at a multiplicity of infection (MOI) of 100. After incubation for an additional 48 hours at 37°C/5% CO 2 , the wells were scored using a fluorescence microscope (Leitz, Stuttgart, Germany); the titer was calculated by determining the dilution at which GFP ϩ HeLa-RC cells could still be detected. All titers are given as biologically active particles. ϩ cells from the leukapheresis product mononuclear cell samples, the MACS MultiSort kit (Miltenyi Biotech, Bergisch Gladbach, Germany) was used. To assess the selection efficiency, a CD34 ϩ restaining was performed. CD34 ϩ purity was 97.96% Ϯ 0.64% as determined by fluorescence-activated cell sorter (FACS) analysis (data not shown). At 24 hours before transduction, 1 ϫ 10 4 cells/well were plated in 24-well plates in 300 L of either ␣MEM (Life Technologies) supplemented with 10% FCS (experiments with sera) or QBSF60 serum-free medium (serum-free experiments; Quality Biological, Inc., Gaithersburg, Md), both with Flt3 ligand (R&D Systems, Wiesbaden, Germany), stem cell factor (R&D Systems) at 100 ng/mL, and thrombopoietin (R&D Systems) at 20 ng/mL.
Cells and cell culture
Transduction
At 1 day before transduction, cells were seeded into 24-well plates at a density of 1 ϫ 10 4 cells/well containing 300 L of their respective media. At 2 hours before transduction, cells were incubated with or without 150 M genistein for 2 hours (37°C/5% CO 2 ). Thereafter, cells were washed twice and respective fresh medium was added. In the serum-free experiments, serum-containing medium was replaced with serumfree medium just before transduction. In all experiments, cells were transduced with rAAV-2 particles at MOIs as described in Results. Cells were cultured for 24 hours in a humidified incubator at 37°C/5% CO 2 , and FCS was subsequently added to the wells (10% vol/vol). Cells were harvested at 60 hours postinfection. They were washed with ice-cold PBS and stored at 4°C for Ͻ15 minutes until acquisition.
Acquisition and analysis
Acquisition and analysis were performed with a FACScalibur flow cytometer (Becton Dickinson, Heidelberg, Germany) mounted with an air-cooled 488-nm argon laser using CellQuest software (Becton Dickinson). For analysis of GFP expression, 10,000 events were acquired. GFP was measured on the FL1 channel (short band pass 530-nm filter) and plotted against side scatter. For each cell line, GFP expression was measured against the respective (uninfected) control cells, thereby correcting for autofluorescence and unspecific (FL1 channel) fluorescence; dead cells and debris were excluded in a forward-sideward scatter plot by gating. Mean fluorescence is given in arbitrary fluorescence units (afu).
Colony-forming cell assay
The concentration of hematopoietic progenitor cells was assessed using a semisolid clonogenic culture assay (MethoCult H4433; Stem Cell Technologies, Vancouver, Canada). The culture medium consisted of 30% FCS, 10% medium conditioned by phytohemagglutinin-stimulated leukocytes, 1 U/mL of recombinant human erythropoietin, 5 ϫ 10 Ϫ5 M 2-mercaptoethanol, and 0.9% methylcellulose. A total of 5 ϫ 10 2
CD34
ϩ mobilized peripheral blood progenitor cells (PBPCs) were plated in duplicate and incubated at 37°C and 5% CO 2 in a humidified atmosphere. After 14 days, colonies were scored using an inverted microscope.
Statistics
Data are presented as mean values Ϯ 1 SE. Significance levels were determined by an (un)paired Student t test.
RESULTS
rAAV-GFP vector and virus production
The rAAV-GFP production procedure reported here did not require coinfection of the producer cells with adenovirus, because the relevant genes are already contained in the pDG helper plasmid. Therefore, the virus batches did not contain adenovirus particles. Until now, no replication-competent AAVs have been observed in viral batches produced with this system. 23 
Infection of mobilized peripheral blood CD34
ϩ cells with rAAV-GFP For a successful application of rAAV-2-vectors in purging setups, the infection rate of CD34
ϩ by rAAV-2 should be as minimal as possible. To test their ability to infect mobilized peripheral blood CD34 ϩ cells, 100 biologically active rAAV-GFP particles/cell were added to fresh CD34 ϩ cells. Cells were allowed to grow and express GFP for 60 hours and were then assayed for GFP expression by FACS analysis. Only 1.39% Ϯ 0.51% of all infected CD34 ϩ cells (range: 0.26% to 2.39%; Fig  1C) expressed GFP over mock-infected control cell levels. The difference in mean fluorescence between rAAV-GFP and mock-infected CD34 ϩ samples was 0.15 afu Ϯ 0.05 afu (range: 0.1-0.26 afu; Fig 1C) .
In the CD34 ϩ cells, the highest transduction efficiency was reached at an MOI of 300 (4.29%; Table 1 ); efficiency could not further be increased by using higher particles per cell concentrations or by enhancing the Data are given as mean Ϯ SEM where multiple experiments were performed (n ϭ 3).
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single-to-double-stranded synthesis by genistein, thereby suggesting that the rate-limiting step in rAAV-2 infection of CD34 ϩ cells is vector uptake.
Infection of breast cancer cell lines T47D and MCF-7 with rAAV-GFP
For the successful use of rAAV-2 vectors in purging protocols, the infection rate of the tumor cells by rAAV-2 should be high. To test the ability of the rAAV-GFP vector to target breast cancer cells, two breast cancer cell lines, T47D and MCF-7, were chosen. Cells were allowed to grow and express GFP for 60 hours and were then assayed for GFP expression by FACS analysis. The proportion of GFP-expressing cells over background and the strength of GFP expression given in afu were analyzed. After infection with rAAV-2 under serum-containing conditions at 100 biologically active particles/cell, 36.06% Ϯ 6.53% of all T47D cells (range: 24.74% to 47.36%; Fig 1A) expressed GFP over mock-infected control cell levels. The difference in mean fluorescence between rAAV-GFP infected and mockinfected T47D samples was 21.52 afu Ϯ 5.92 afu (range: 10.77-31.21 afu; Fig 1A) . A total of 41.52% Ϯ 3.16% of all MCF-7 cells (range: 36.02% to 46.96%; Fig 1B) expressed GFP over mock-infected control cell levels. The difference in mean fluorescence between rAAV-GFP-infected and mock-infected MCF-7 samples was 41.30 afu Ϯ 10.66 afu (range: 24.35-60.98 afu; Fig 1B) .
To increase transduction efficiencies, additional experiments were performed with serum-free media during transduction to avoid possible binding of rAAV-2 particles to components in sera. For both breast cancer cell lines, there was a significant increase in infection rates (percentage of GFP-expressing cells) at an MOI of 100 in the serum-free group (Table 1) compared with the serum-containing group (Fig 1, I ; T47D, P ϭ .019; MCF-7, P ϭ .001). Similarly, the strength of expression (mean fluorescence intensity) of cells infected under serum-free conditions at an MOI of 100 (Fig 2) was significantly higher for T47D (P ϭ .02) than after infection in serum-containing media; a similar trend was observed for MCF-7 (P ϭ .06; Fig 1, II) .
To assess the phosporylation state of the ssD-BP for both cell lines, samples were preincubated with or without 150 M genistein for 2 hours. An increase in infection rates (percentage of GFP-expressing cells; T47D cells, P ϭ .012; MCF-7 cells, P ϭ .26) and in the strength of expression (mean fluorescence intensity; T47D, P Ͻ .00001; MCF-7, P ϭ .002) was observed when samples were preincubated with genistein.
Over an MOI range of 100 -500 with (r ϭ 0.77, P ϭ .04) or without (r ϭ 0.57, P ϭ .18) genistein pretreatment for T47D cells and over an MOI range of 100 -500 with (r ϭ 0.67, P ϭ .10) or without genistein (r ϭ 0.62, P ϭ .14) pretreatment for MCF-7 cells, a trend (only significant for genistein-treated T47D cells) between the ratio of infectious particles per cell and the mean infection rate (percentage of GFP ϩ cells) was observed under serum-free conditions. A steep increase in transduction efficiency could be seen between an MOI of 100 and 200 (from 58.68% to 76.29%; Table 1 ) for T47D cells, thereby suggesting a suboptimal saturation of the AAV-2 receptors at an MOI of 100 and implying that testing of efficient dose levels is required for each cell line/type. Correlation analysis between MOI (100 -500) and mean fluorescence intensity under serum-free conditions (Fig 2) showed that for MCF-7 only a trend could be detected (no genistein: r ϭ 0.737, P ϭ .058; genistein: r ϭ 0.634, P ϭ .125); however, a significant correlation was seen for T47D (no genistein: r ϭ 0.91, P ϭ .005; genistein: r ϭ 0.95, P ϭ .001). At a higher MOI of 300 -500, no significant increase in the percentage of GFP ϩ cells could be observed for both breast cancer cell lines; however, a further increase in mean fluorescence intensity could be observed at increasing MOIs.
DISCUSSION
Infection of mobilized peripheral blood CD34
ϩ cells with rAAV-GFP The present study describes the susceptibility of mobilized peripheral blood CD34 ϩ cells and the breast cancer cell lines T47D and MCF-7 for infection by the rAAV-GFP vector and expression of this vector. As already pointed out, the infection rate of hematopoietic progenitor cells by rAAV-2 should be low for purging setups. Although several groups claimed to be able to infect CD34 ϩ cells relatively efficiently with rAAV-2, 26, 27 others showed inefficient infection of these cells. 28 Ponnazhagan et al 29 showed that the susceptibility of CD34 ϩ cells for rAAV-2 varied from donor to donor, and that this susceptibility seemed to be the result of variations in the expression of the AAV-2 receptor. Our data are in line with the low-efficiency groups: only 1.39% Ϯ 0.51% of all rAAV-2-infected mobilized peripheral blood CD34 ϩ cells (at an MOI of 100) expressed GFP. The expression level was marginally higher than in control cells (0.15 afu Ϯ 0.05 afu). The huge variation in rAAV-2 infection rates of CD34 ϩ cells from different donors, as described by Ponnazhagan et al, 29 was not observed in our experiments shown here.
Although no significant expression of our rAAV-2 vector was observed in human CD34
ϩ PBPCs, rAAV-2 infection of CD34 ϩ progenitor cells might have a possible toxic effect; therefore, this effect was assayed using semisolid methyl-cellulose cultures. These clonogenic assays did not indicate any inhibitory effects on the cloning efficiency or on the differentiation ability of the CD34 ϩ cells by the rAAV-2 vector at an MOI of 100 (relative colony-forming unit count of untreated control ϭ 100; relative colony-forming unit count of the rAAV-2 group ϭ 162).
Some variables could account for the discrepancy in the data (e.g., virus-stock preparations, stock purity, wt AAV-2 contamination, the presence of adenovirus or other helper virus, and rAAV-2 construction and design). Interestingly, publications reporting efficient infection of CD34 ϩ cells were published before 1995, (n ϭ 3) .
VELDWIJK, FRUEHAUF, SCHIEDLMEIER, ET AL: rAAV FOR PREFERENTIAL TUMOR CELL INFECTION
whereas those suggesting rather low or inefficient infection rates of CD34 ϩ cells were published more recently. Apparently, technically superior rAAV-2 production protocols and vectors rule out other influences, which possibly can enhance the infection rate in other ways aside from rAAV-2-mediated gene transfer. A recent publication 28 underlined the importance of purification steps in the rAAV-2 production procedure, reporting that contamination of rAAV-2 virus stock by reporter genes could result in artificially introduced overestimation by so-called pseudotransduction. Furthermore, infection could readily be enhanced by contamination with wt AAV-2 by rescuing the rAAV-2 vectors or possibly by generating replication-competent recombinant/wt AAV-2 hybrids. 15, 30 Recombinant/wt AAV-2 generation/expression could be even further enhanced by adenovirus contamination. The procedure for rAAV-GFP vector production used in this study did not require wt adenovirus coinfection, because all adenoviral genes required for AAV-2 helper function were contained on a helper plasmid. 23 Also, this vector is not known to produce any wt AAV-2, because wt AAV-2 generation has not been observed yet. 23 This is an advantage for possible in vivo applications of this vector system, because the rAAV-2 batches produced with this procedure do not contain immunogenic adenoviral contaminants or contaminating and replicating wt AAV-2. Furthermore, a purification and concentration step during rAAV-2 production was introduced using a modified purification and concentration procedure by Tamayose et al. 24 Possible reasons for the low infection efficiency of rAAV-2 vectors in human hematopoietic progenitor cells were recently provided. Qing et al 31 reported that the efficiency of rAAV-2-mediated gene transfer correlated with the tyrosine phosphorylation state of the cellular ssD-BP. In both human erythroid leukemia cell lines and in primary human CD34 ϩ progenitor cells, the protein was phosphorylated, resulting in a lower efficiency of rAAV-2-mediated gene expression. Whereas in our experiments preincubation of the breast cancer cells with genistein resulted in an overall increase in transduction efficiencies as well as transgene expression levels, only marginally higher infection and expression levels were observed with the genistein-pretreated CD34 ϩ PBPCs (Table 1, Fig 2) . Summerford and Samulski showed that a receptor mediating AAV-2 infection is a membrane-associated heparan sulfate proteoglycan (HSPG). 32 Recently, two groups 33,34 discovered two other receptors involved in AAV-2 cell binding and entrance, the human fibroblast growth factor receptor-1 (FGFR-1) and an ␣ 5 ␤ V integrin. It seems that the HSPG functions as a primary receptor and the FGFR-1 and ␣ 5 ␤ V integrin function as coreceptors. Qing et al showed that the availability of HSPG alone is not sufficient for AAV-2 infection, and that both the HSPG and FGFR-1 receptors are required for efficient infection with AAV-2. Although the HSPG receptor seems to be expressed on most cell types, the other two receptors are less common and may explain the differences in the infection rates of different cells types by AAV-2. Recently, interesting results describing the infection of CD34 ϩ progenitors with rAAV-2 vectors were published by Chatterjee et al. 35 They showed that these cells could be readily infected and that the progeny of the CD34 ϩ cells contained vector sequences over a period of 10 weeks, whereby a high variation in infection rates between different donor samples was observed (range: 5-100% vector-DNA-positive cells) when cells were derived from cord blood or bone marrow. Poor transduction rates in cytokine-mobilized PBPCs, which were used in our study, were described by Chatterjee et al. Our data on breast cancer cell purging from PBPC samples may therefore not be transferable to the purging of autologous bone marrow from tumor patients.
It seems that there are quite a few cell characteristics that influence whether or not rAAV-2 vectors can infect a type of cells; for the CD34 ϩ mobilized PBPCs, at least one of these characteristics seems to be missing, thereby causing a relatively high resistance to rAAV-2 infection.
Infection of breast cancer cell lines T47D and MCF-7 with rAAV-GFP In contrast to the low infection rate of CD34 ϩ progenitors (1.39% Ϯ 0.51%), both breast cancer cell lines (T47D and MCF-7) could readily be infected. Whereas 36.06% Ϯ 6.53% of T47D cells were infected with the vector and expressed GFP (⌬ mean fluorescence: 21.52 afu Ϯ 5.92 afu), MCF-7 cells were even more susceptible to rAAV-GFP, with infection rates of 41.52% Ϯ 3.16% (⌬ mean fluorescence: 41.30 afu Ϯ 10.66 afu). Replacement of serum-containing media with serum-free media during transduction and the use of the ssD-BP inhibitor genistein resulted in even higher percentages of GFPexpressing cells as well as higher transgene expression levels ( Table 1, Fig 2) . At higher MOIs, the transduction efficiencies reached a plateau level, although an increase in mean fluorescence intensity could still be observed, suggesting multiple integrations of rAAV-2 in both T47D and MCF-7 cells.
Possible use of rAAV-2 vectors for breast cancer cell purging strategies It seems that breast cancer cells are particularly susceptible to rAAV-2, whereas peripheral blood CD34 ϩ progenitors could hardly be transduced. The concern that cell lines might be more permissive to rAAV-2 than primary cells has recently been defused by Maass et al. 21 They showed that some primary tumors were surprisingly more susceptible to rAAV-2 than cell lines. These observations and the growing indication for the use of high-dose chemotherapy with mobilized peripheral blood support in the battle against breast cancer could render rAAV-2 vectors containing suicide genes, such as thymidine kinase 36 and cytosine deaminase, 37 good candidates for tumor cell purging, which may be included in current purging protocols.
The recently published preliminary results from a phase III clinical trial 38 showed no significant difference in overall survival between high-dose chemotherapy with stem cell support and breast cancer patients treated according to standard dose protocols. Furthermore, the role of tumor cells contaminating an autograft for the induction of a clinical relapse has not been defined, because randomized studies on the role of purging in breast cancer are lacking. However, our AAV gene transfer approach may serve as a model system for other solid tumors that are also treated with high-dose therapy and stem cell support.
